Research programme: oncolytic viruses - Transgene

Drug Profile

Research programme: oncolytic viruses - Transgene

Alternative Names: anti-PD-1 immune checkpoint inhibitor - Transgene; J43-armed-Western Reserve oncolytic vaccinia virus; TG 6002; VV-TK-RR-FCU1; VVWR-TK-RR--Fcu1

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Transgene
  • Class Antibodies; Antineoplastics; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators; PDCD 1 protein inhibitors; Prodrug activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 17 May 2017 Pharmacodynamic data from a preclinical trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 30 Mar 2017 Interim data from preclinical study in Solid tumours released by Transgene
  • 20 Mar 2017 Transgene files for patent protection for an oncolytic Vaccinia Virus expressing an anti-PD1 antibody in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top